Skip to main content
Medical information Clinical review pending

Genetic Testing

CAPN3 Gene Muscular Dystrophy Limb-Girdle Type 2A Genetic Test

Genetic test to identify mutations in the CAPN3 gene associated with Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A).

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history review and genetic counseling session, including pedigree chart creation, are typically required before testing. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CAPN3 Gene Muscular Dystrophy Limb-Girdle Type 2A Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of Limb-Girdle Muscular Dystrophy (LGMD)
  • ✓Family history of LGMD or related muscle disorders
  • ✓Genetic counseling for family planning
  • ✓Confirmation of suspected LGMD2A diagnosis
  • ✓Differential diagnosis of muscle weakness
02

In plain language

What this test helps you understand

Identifies mutations in the CAPN3 gene associated with Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A), aiding in diagnosis and genetic counseling.
The CAPN3 Gene Muscular Dystrophy Limb-Girdle Type 2A NGS Genetic DNA Test is an advanced diagnostic tool used to identify mutations in the CAPN3 gene. These mutations are linked to Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A), a condition causing progressive muscle weakness, particularly in the hips and shoulders. Understanding your genetic status can help with health management and family planning.

This test uses Next Generation Sequencing (NGS) technology to analyze your DNA for specific changes in the CAPN3 gene. It helps confirm if these genetic alterations are present, which may lead to the development of LGMD2A.

Individuals with symptoms like muscle weakness, difficulty walking, or muscle wasting, or those with a family history of muscular dystrophy, may benefit from this test. It is also useful for genetic counseling related to family planning.

Taking this test can provide accurate identification of genetic predispositions, support informed decisions about treatment and lifestyle, and help understand risks for family members. Our genetic specialists will interpret your results and discuss management strategies if mutations are found. Negative results can help rule out this specific genetic cause.

To book your test, please call or WhatsApp us at +254711564616. We have branches across major cities in Kenya and offer home sample collection.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history review and genetic counseling session, including pedigree chart creation, are typically required before testing. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) analysis of the CAPN3 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the CAPN3 gene. It will not detect mutations in other genes associated with LGMD or other neuromuscular disorders. A negative result does not completely rule out LGMD if other genetic causes are possible. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

LGMD2A is a genetic disorder causing progressive muscle weakness, primarily affecting the muscles around the hips and shoulders.
This test looks for specific genetic mutations in the CAPN3 gene that are known to cause LGMD2A.
Individuals experiencing muscle weakness, difficulty walking, or muscle wasting, especially with a family history of muscular dystrophy, should consider this test.
A genetic specialist will interpret the results. Positive results indicate mutations associated with LGMD2A, while negative results suggest these specific mutations are not present.
Typically, a blood sample is required. Please confirm the exact specimen requirements with the laboratory.
Results are typically available within 3 to 4 weeks, but this can vary. Confirm the current turnaround time with the laboratory.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp